Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study.

Aakash Desai,Jana G Hashash,Gursimran S Kochhar,Francis A Farraye

Crohn's & colitis 360（2023）

引用 0|浏览3

暂无评分

摘要

Our study did not show that Evusheld decreases the risk of COVID-19 in patients with IBD. Prevention of moderate-severe COVID-19 in these patients should focus on vaccination strategies and early COVID-19 therapies.

查看译文

关键词

inflammatory bowel disease, COVID-19, tixagevimab, cilgavimab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要